Paxlovid Receives FDA Approval for COVID-19 Treatment
The is the first approval of an oral antiviral therapy for COVID-19.
Rates of HIV decreased for those aged 13 to 24 years and for infections attributable to male-to-male sexual contact.
Aerobic activity, even below recommended level, linked to lower mortality, while J-shaped pattern seen for muscle-strengthening activity.
Extension through November 11, 2023, gives DEA and HHS a chance to consider revisions and public comments regarding proposals offered March 1.
Evidence shows the 2022 to 2023 season is a return toward prepandemic seasonality.